Antiischemic effects of intravenous diazepam in patients with coronary artery disease

Enrico Rossetti, Gabriele Fragasso, Robert G. Xuereb, Mariosa Xuereb, Alberto Margonato, Sergio L. Chierchia

Research output: Contribution to journalArticle

Abstract

Diazepam (DZP) is commonly used in treatment of patients with acute ischemic syndromes to allay anxiety, but benzodiazepines reduce myocardial contractility and increase myocardial blood flow. To investigate the antiischemic effect of DZP, we studied 13 patients with a positive exercise test and angiographically documented coronary artery disease. AU patients were submitted to a randomized, placebo-controlled trial using 0.9% NaCI infusion as placebo and intravenous (i.v.) diazepam (0.1 mg/kg in 20 min). Exercise tests performed immediately after the infusions showed that as compared with placebo, DZP significantly prolonged time to I-mm ST-segment depression (557 ± 198 vs. 428 ± 226 s, p <0.0001) and total exercise duration (624 ± 177 vs. 561 ± 188 s, p <0.007). Rate-pressure product (RPP) at 1-mm ST-segment depression was not significantly different with the two treatments. DZP significantly delays onset of exercise-induced myocardial ischemia in patients with coronary artery disease. Because RPP at onset of ischemia was similar to that recorded with placebo despite greater levels of external workload, the antiischemic action of DZP appears to be mediated, at least partially, by a reduction in myocardial oxygen consumption. Key Words: Diazepam-Coronary artery disease-Exercise testing.

Original languageEnglish
Pages (from-to)55-58
Number of pages4
JournalJournal of Cardiovascular Pharmacology
Volume24
Issue number1
Publication statusPublished - 1994

Fingerprint

Diazepam
Coronary Artery Disease
Placebos
Exercise
Exercise Test
Pressure
Workload
Benzodiazepines
Oxygen Consumption
Myocardial Ischemia
Ischemia
Anxiety
Randomized Controlled Trials
Therapeutics

Keywords

  • Coronary artery disease
  • Diazepam
  • Exercise testing

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Antiischemic effects of intravenous diazepam in patients with coronary artery disease. / Rossetti, Enrico; Fragasso, Gabriele; Xuereb, Robert G.; Xuereb, Mariosa; Margonato, Alberto; Chierchia, Sergio L.

In: Journal of Cardiovascular Pharmacology, Vol. 24, No. 1, 1994, p. 55-58.

Research output: Contribution to journalArticle

Rossetti, Enrico ; Fragasso, Gabriele ; Xuereb, Robert G. ; Xuereb, Mariosa ; Margonato, Alberto ; Chierchia, Sergio L. / Antiischemic effects of intravenous diazepam in patients with coronary artery disease. In: Journal of Cardiovascular Pharmacology. 1994 ; Vol. 24, No. 1. pp. 55-58.
@article{3ed013fbf73249d6bf10d7a93aa4baa7,
title = "Antiischemic effects of intravenous diazepam in patients with coronary artery disease",
abstract = "Diazepam (DZP) is commonly used in treatment of patients with acute ischemic syndromes to allay anxiety, but benzodiazepines reduce myocardial contractility and increase myocardial blood flow. To investigate the antiischemic effect of DZP, we studied 13 patients with a positive exercise test and angiographically documented coronary artery disease. AU patients were submitted to a randomized, placebo-controlled trial using 0.9{\%} NaCI infusion as placebo and intravenous (i.v.) diazepam (0.1 mg/kg in 20 min). Exercise tests performed immediately after the infusions showed that as compared with placebo, DZP significantly prolonged time to I-mm ST-segment depression (557 ± 198 vs. 428 ± 226 s, p <0.0001) and total exercise duration (624 ± 177 vs. 561 ± 188 s, p <0.007). Rate-pressure product (RPP) at 1-mm ST-segment depression was not significantly different with the two treatments. DZP significantly delays onset of exercise-induced myocardial ischemia in patients with coronary artery disease. Because RPP at onset of ischemia was similar to that recorded with placebo despite greater levels of external workload, the antiischemic action of DZP appears to be mediated, at least partially, by a reduction in myocardial oxygen consumption. Key Words: Diazepam-Coronary artery disease-Exercise testing.",
keywords = "Coronary artery disease, Diazepam, Exercise testing",
author = "Enrico Rossetti and Gabriele Fragasso and Xuereb, {Robert G.} and Mariosa Xuereb and Alberto Margonato and Chierchia, {Sergio L.}",
year = "1994",
language = "English",
volume = "24",
pages = "55--58",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Antiischemic effects of intravenous diazepam in patients with coronary artery disease

AU - Rossetti, Enrico

AU - Fragasso, Gabriele

AU - Xuereb, Robert G.

AU - Xuereb, Mariosa

AU - Margonato, Alberto

AU - Chierchia, Sergio L.

PY - 1994

Y1 - 1994

N2 - Diazepam (DZP) is commonly used in treatment of patients with acute ischemic syndromes to allay anxiety, but benzodiazepines reduce myocardial contractility and increase myocardial blood flow. To investigate the antiischemic effect of DZP, we studied 13 patients with a positive exercise test and angiographically documented coronary artery disease. AU patients were submitted to a randomized, placebo-controlled trial using 0.9% NaCI infusion as placebo and intravenous (i.v.) diazepam (0.1 mg/kg in 20 min). Exercise tests performed immediately after the infusions showed that as compared with placebo, DZP significantly prolonged time to I-mm ST-segment depression (557 ± 198 vs. 428 ± 226 s, p <0.0001) and total exercise duration (624 ± 177 vs. 561 ± 188 s, p <0.007). Rate-pressure product (RPP) at 1-mm ST-segment depression was not significantly different with the two treatments. DZP significantly delays onset of exercise-induced myocardial ischemia in patients with coronary artery disease. Because RPP at onset of ischemia was similar to that recorded with placebo despite greater levels of external workload, the antiischemic action of DZP appears to be mediated, at least partially, by a reduction in myocardial oxygen consumption. Key Words: Diazepam-Coronary artery disease-Exercise testing.

AB - Diazepam (DZP) is commonly used in treatment of patients with acute ischemic syndromes to allay anxiety, but benzodiazepines reduce myocardial contractility and increase myocardial blood flow. To investigate the antiischemic effect of DZP, we studied 13 patients with a positive exercise test and angiographically documented coronary artery disease. AU patients were submitted to a randomized, placebo-controlled trial using 0.9% NaCI infusion as placebo and intravenous (i.v.) diazepam (0.1 mg/kg in 20 min). Exercise tests performed immediately after the infusions showed that as compared with placebo, DZP significantly prolonged time to I-mm ST-segment depression (557 ± 198 vs. 428 ± 226 s, p <0.0001) and total exercise duration (624 ± 177 vs. 561 ± 188 s, p <0.007). Rate-pressure product (RPP) at 1-mm ST-segment depression was not significantly different with the two treatments. DZP significantly delays onset of exercise-induced myocardial ischemia in patients with coronary artery disease. Because RPP at onset of ischemia was similar to that recorded with placebo despite greater levels of external workload, the antiischemic action of DZP appears to be mediated, at least partially, by a reduction in myocardial oxygen consumption. Key Words: Diazepam-Coronary artery disease-Exercise testing.

KW - Coronary artery disease

KW - Diazepam

KW - Exercise testing

UR - http://www.scopus.com/inward/record.url?scp=0028364799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028364799&partnerID=8YFLogxK

M3 - Article

C2 - 7521490

AN - SCOPUS:0028364799

VL - 24

SP - 55

EP - 58

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 1

ER -